Abivax SA, a prominent biotechnology company headquartered in Paris, France, continues to make significant strides in the healthcare sector, particularly in the development of anti-viral therapies and therapeutic vaccines. As a company incorporated in 2013, Abivax SA has established itself as a key player in addressing infectious diseases prevalent in Asia and Latin America. The company’s innovative approach is evident in its diverse portfolio of products and clinical trials.
At the forefront of Abivax SA’s pipeline is ABX 464, a promising candidate currently in Phase II clinical trials. This therapy aims to provide sustained viral remission or a functional cure for patients with HIV/AIDS, marking a potential breakthrough in the treatment of this chronic condition. Additionally, ABX 203, a therapeutic vaccine candidate, is advancing through Phase IIb/III trials for the treatment of chronic hepatitis B, showcasing the company’s commitment to tackling viral infections.
ABX 196, another notable candidate, has completed Phase I clinical trials as an art immune enhancer targeting iNKT cells. This development underscores Abivax SA’s focus on enhancing immune responses to combat infectious diseases. The company’s vaccine development efforts extend to typhoid, meningitis B and C, and leptospirosis, further broadening its impact on global health.
In its pre-clinical programs, Abivax SA is exploring innovative solutions for other infectious diseases. ABX 220 is being developed for the treatment of Dengue fever, while ABX 544, a drug candidate based on polyclonal antibodies, targets Ebola. Additionally, ABX 311 is in the pipeline for the treatment of Chikungunya, reflecting the company’s proactive approach to emerging health threats.
Abivax SA’s strategic collaborations and partnerships are pivotal to its success. The company has established license contracts with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Furthermore, its partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia highlights its international reach and collaborative spirit.
Despite facing challenges, as indicated by a negative price-earnings ratio of -15.45, Abivax SA’s market capitalization stands at 6.89 billion EUR, reflecting investor confidence in its long-term potential. The company’s stock is actively traded on the NYSE Euronext Paris, with a close price of 79 EUR as of October 8, 2026. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 139 EUR and a low of 60.45 EUR.
As Abivax SA continues to advance its clinical trials and expand its therapeutic offerings, it remains a key player in the biotechnology sector, dedicated to improving global health outcomes through innovative solutions. The company’s forward-looking approach and strategic partnerships position it well to address the evolving landscape of infectious diseases. For more information, stakeholders and interested parties can visit the official website at www.abivax.com .
